ES2544942T3 - Células diferenciadas adecuadas para tratamiento humano - Google Patents
Células diferenciadas adecuadas para tratamiento humano Download PDFInfo
- Publication number
- ES2544942T3 ES2544942T3 ES01986488.3T ES01986488T ES2544942T3 ES 2544942 T3 ES2544942 T3 ES 2544942T3 ES 01986488 T ES01986488 T ES 01986488T ES 2544942 T3 ES2544942 T3 ES 2544942T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- cell
- differentiated cells
- cells suitable
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004027 cell Anatomy 0.000 abstract description 42
- 210000000130 stem cell Anatomy 0.000 abstract description 6
- 150000007523 nucleic acids Chemical class 0.000 abstract description 4
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 231100000518 lethal Toxicity 0.000 abstract 2
- 230000001665 lethal effect Effects 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 239000002243 precursor Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una molécula de ácido nucleico que comprende la estructura P-X, en la que: X es una secuencia de ácidos nucleicos que codifica un producto que es letal para una célula en la que se expresa o hace una célula en la que se expresa susceptible de un efecto letal de un agente externo y P es un elemento de control transcripcional que produce que X se exprese preferiblemente en células madre pluripotentes de primate (pPS) no diferenciadas.
Description
5
15
25
35
45
55
65
E01986488
10-08-2015
en colonias de células con altas relaciones nuclear/citoplasmática y nucleolos prominentes. Se entiende que las colonias de células no diferenciadas dentro de la población con frecuencia estarán rodeadas por células vecinas que sean diferenciadas. Sin embargo, las colonias no diferenciadas persisten cuando se cultiva la población o se hacen pases en las condiciones apropiadas y las células no diferenciadas individuales constituyen una proporción sustancial de la población celular. Los cultivos que están sustancialmente no diferenciados contienen al menos 20% de células pPS no diferenciadas y pueden contener al menos 40%, 60% u 80% en orden de preferencia creciente. Siempre que se refiera un cultivo o población celular en esta descripción como proliferación "sin diferenciación", lo que se quiere decir es que después de proliferación, la composición es sustancialmente no diferenciada de acuerdo con la definición precedente.
"Células alimentadoras" o "alimentadores" son términos usados para describir células de un tipo que se cultivan conjuntamente con células de otro tipo, para proporcionar un entorno en el que las células del segundo tipo puedan crecer. Las células alimentadoras son opcionalmente de una especie diferente que las células que están soportando. Por ejemplo, ciertos tipos de células pPS se pueden soportar por fibroblastos embrionarios de ratón primarios, fibroblastos embrionarios de ratón inmortalizados o células de tipo fibroblasto humano diferenciadas de células hES, como se describe más adelante en esta descripción. Se dice que las poblaciones de células pPS están "esencialmente exentas" de células alimentadoras si las células han sido cultivadas a través de al menos un ciclo después de la división en que no se añaden células alimentadoras frescas para soportar el crecimiento de la pPS. Los cultivos esencialmente exentos de células alimentadoras contienen menos de aproximadamente 5% de células alimentadoras. Siempre que un cultivo o una población celular se refiera en esta descripción como "exento de alimentador", lo que se quiere decir es que la composición está esencialmente exenta de células alimentadoras de acuerdo con la definición precedente, sujeta sólo a restricciones adicionales requeridas de manera explícita.
El término "cuerpos embrioides" es un término de sinónimo de la técnica con "cuerpos agregados". Los términos se refieren a agregados de células diferenciadas y no diferenciadas que aparecen cuando se multiplican células pPS en cultivos monocapa o se mantienen en cultivos en suspensión. Los cuerpos embrioides son una mezcla de diferentes tipos de células, típicamente de varias capas germinativas, distinguibles por criterios morfológicos.
Los términos "células precursoras comprometidas", "células precursoras de linaje restringido" y "células de linaje de desarrollo restringido" se refieren todos a células que son capaces de proliferar y diferenciarse en diversos tipos de células diferentes, con un intervalo que es típicamente más limitado que las células madre pluripotentes de origen embrionario capaces de dar lugar a progenie de las tres capas germinativas. Ejemplos no limitantes de células precursoras comprometidas incluyen células hematopoyéticas, que son pluripotentes para varias células sanguíneas; progenitores de hepatocitos que son pluripotentes para células epiteliales de las vías biliares y hepatocitos y células madres mesenquimales. Otro ejemplo son células neurales restringidas, que pueden generar precursores de células gliales que progresan a oligodendrocitos y astrocitos y precursores neuronales que progresan a neuronas.
Para los fines de esta descripción, el término "célula madre" puede referirse a una célula madre pluripotente o una célula precursora comprometida, ambas como se definió anteriormente. Mínimamente, una célula madre presenta la capacidad para proliferar y formar células de más de un fenotipo diferente y también es capaz de auto-renovación - como parte del mismo cultivo o cuando se cultiva en diferentes condiciones. Las células madre embrionarias se pueden identificar como positivas para la enzima telomerasa.
Como se usa en esta descripción, "diferenciada" y "no diferenciada" son términos relativos dependiendo del contexto en que se usen. Específicamente, en referencia a un tipo particular de célula madre auto-renovadora, el término "no diferenciada" se refiere de nuevo a la misma célula madre auto-renovadora, mientras el término "diferenciada" se refiere a uno o más de los fenotipos relativamente maduros que puede generar la célula madre - como es apreciable por criterios morfológicos, marcadores antigénicos y transcripciones génicas que producen. Las células pPS no diferenciadas presentan la capacidad para diferenciarse en tres capas germinativas. Las células diferenciadas de ellas no y se pueden reconocer fácilmente por un experto en la materia por criterios morfológicos.
Los términos "polinucleótido" y "molécula de ácido nucleico" se refieren a un polímero de nucleótidos de cualquier longitud. Se incluyen genes y fragmentos de genes, ARNm, ARNt, ARNr, ribozimas, ADNc, polinucleótidos recombinantes, polinucleótidos ramificados, plásmidos, vectores, ADN y ARN aislados, sondas de ácidos nucleicos y cebadores. Como se usa en esta descripción, el término polinucleótidos se refiere de manera intercambiable a moléculas bicatenarias y monocatenarias. A menos que se especifique o se requiera de otro modo, cualquier realización de la invención que sea un polinucleótido incluye tanto una forma bicatenaria como cada una de las dos formas monocatenarias complementarias conocidas o previstas para constituir la forma bicatenaria. Se incluyen análogos de ácidos nucleicos tales como fosporamidatos y tiofosforamidatos.
Se dice que una célula es "modificada genéticamente", "transinfectada" o "genéticamente transformada" cuando un polinucleótido ha sido transferido a la célula por cualquier medio adecuado de manipulación artificial o en el caso de que la célula sea una progenie de la célula modificada originalmente que haya heredado el polinucleótido. El polinucleótido con frecuencia comprenderá una secuencia que se pueda transcribir que codifique una proteína de
7
Claims (1)
-
imagen1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25344300P | 2000-11-27 | 2000-11-27 | |
| US25335700P | 2000-11-27 | 2000-11-27 | |
| US253357P | 2000-11-27 | ||
| US253443P | 2000-11-27 | ||
| US783203 | 2001-02-13 | ||
| US09/783,203 US6576464B2 (en) | 2000-11-27 | 2001-02-13 | Methods for providing differentiated stem cells |
| PCT/US2001/044309 WO2002042445A2 (en) | 2000-11-27 | 2001-11-26 | Differentiated cells suitable for human therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2544942T3 true ES2544942T3 (es) | 2015-09-07 |
Family
ID=27400669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01986488.3T Expired - Lifetime ES2544942T3 (es) | 2000-11-27 | 2001-11-26 | Células diferenciadas adecuadas para tratamiento humano |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US6576464B2 (es) |
| EP (1) | EP1337632B1 (es) |
| JP (1) | JP2004523217A (es) |
| KR (1) | KR20030081334A (es) |
| CN (2) | CN101928692A (es) |
| AU (2) | AU3768102A (es) |
| CA (1) | CA2434760C (es) |
| ES (1) | ES2544942T3 (es) |
| GB (1) | GB2386120B (es) |
| IL (2) | IL155695A0 (es) |
| WO (1) | WO2002042445A2 (es) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7351578B2 (en) | 1999-12-10 | 2008-04-01 | Invitrogen Corp. | Use of multiple recombination sites with unique specificity in recombinational cloning |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| WO2001029206A1 (en) * | 1999-10-15 | 2001-04-26 | Advanced Cell Technology, Inc. | Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US6921665B2 (en) * | 2000-11-27 | 2005-07-26 | Roslin Institute (Edinburgh) | Selective antibody targeting of undifferentiated stem cells |
| US6576464B2 (en) * | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| US20030104426A1 (en) * | 2001-06-18 | 2003-06-05 | Linsley Peter S. | Signature genes in chronic myelogenous leukemia |
| WO2003034985A2 (en) * | 2001-10-22 | 2003-05-01 | University Of Rochester | Telomerase interference |
| IL162130A0 (en) | 2001-12-07 | 2005-11-20 | Robarts Res Inst | Hematopoietic cells from human embryonic stem cells |
| US7595043B2 (en) | 2001-12-07 | 2009-09-29 | Cytori Therapeutics, Inc. | Method for processing and using adipose-derived stem cells |
| US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| KR100930139B1 (ko) * | 2001-12-07 | 2009-12-07 | 사이토리 테라퓨틱스, 인크. | 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법 |
| US7651684B2 (en) | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
| US20050048035A1 (en) | 2001-12-07 | 2005-03-03 | Fraser John K. | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
| US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
| US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
| US8404229B2 (en) | 2001-12-07 | 2013-03-26 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to treat acute tubular necrosis |
| US7514075B2 (en) | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
| US9597395B2 (en) * | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
| US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
| US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
| EP1472340A4 (en) * | 2002-02-05 | 2006-11-08 | Rappaport Family Inst For Res | STEM CELLS DETERMINED FOR A LINE SELECTED FOR THE PROMOTER ACTIVITY OF TELOMERASE |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US20050265983A1 (en) * | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
| US20050014116A1 (en) * | 2002-11-27 | 2005-01-20 | Reid Gregory S. | Testing information comprehension of contact center users |
| US20040214324A1 (en) * | 2002-12-09 | 2004-10-28 | Ole Isacson | Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases |
| AU2003303071B2 (en) | 2002-12-16 | 2009-04-23 | Technion Research & Development Foundation Ltd. | Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same |
| US20060211111A1 (en) * | 2002-12-18 | 2006-09-21 | Maisam Mitalipova | Compositions and methods for neural cell production and stabilization |
| US7153650B2 (en) | 2003-03-13 | 2006-12-26 | Geron Corporation | Marker system for preparing and characterizing high-quality human embryonic stem cells |
| US20060281136A1 (en) * | 2003-05-20 | 2006-12-14 | Shinichi Nishikawa | Preparation of endodermal stem cells |
| EP2578676A1 (en) | 2003-06-20 | 2013-04-10 | Axiogenesis Ag | Tissue modeling in multi- or pluripotent cell systems |
| AR046076A1 (es) * | 2003-07-18 | 2005-11-23 | Otsuka Pharma Co Ltd | Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida |
| US20050054100A1 (en) * | 2003-09-08 | 2005-03-10 | Rennard Stephen I. | Methods for fibroblast differentiation |
| WO2005054438A2 (en) | 2003-12-01 | 2005-06-16 | Invitrogen Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
| EP2929782A1 (en) * | 2004-01-23 | 2015-10-14 | Ocata Therapeutics, Inc. | Improved modalities for the treatment of degenerative diseases of the retina |
| US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| WO2005079849A2 (en) * | 2004-02-25 | 2005-09-01 | Zgene A/S | Compounds for enhanced cancer therapy |
| US20050277124A1 (en) * | 2004-06-10 | 2005-12-15 | White Steven M | Cardiac conduction system cells and uses thereof |
| WO2006014159A2 (en) * | 2004-07-01 | 2006-02-09 | Macropore Biosurgery Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
| WO2006044204A2 (en) * | 2004-10-05 | 2006-04-27 | University Of Georgia Research Foundation, Inc. | Neuronal progenitors from feeder-free human embryonic stem cell culture |
| US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
| US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
| JP5006312B2 (ja) * | 2005-05-27 | 2012-08-22 | エイジェンシー フォー サイエンス， テクノロジー アンド リサーチ | バキュロウイルスベクターを使用して核酸分子を胚性幹細胞に送達する方法 |
| EP2465924A3 (en) | 2005-06-16 | 2013-01-02 | Ramot at Tel-Aviv University Ltd. | Isolated cells and populations comprising same for the treament of cns diseases |
| JP5560391B2 (ja) | 2005-06-22 | 2014-07-23 | アステリアス バイオセラピューティクス インコーポレイテッド | ヒト胚性幹細胞の懸濁培養法 |
| EP1962719A4 (en) | 2005-08-29 | 2011-05-04 | Technion Res And Dev Of Foundation Ltd | MEDIA FOR BREEDING STEM CELLS |
| CN1966080B (zh) * | 2005-11-17 | 2011-06-08 | 李凌松 | 一种治疗老年痴呆症、帕金森病的神经干细胞注射液 |
| US20100021434A1 (en) * | 2005-12-08 | 2010-01-28 | Ramot At Tel Aviv University Ltd. | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases |
| WO2007139551A1 (en) * | 2006-05-30 | 2007-12-06 | Cytori Therapeutics, Inc. | Systems and methods for manipulation of regenerative cells from adipose tissue |
| WO2008013863A2 (en) * | 2006-07-26 | 2008-01-31 | Cytori Therapeutics, Inc. | Generation of adipose tissue and adipocytes |
| DK3441459T3 (da) | 2006-08-02 | 2021-06-07 | Technion Res & Dev Foundation | Fremgangsmåder til ekspansion af embryonale stamceller i en suspensionskultur |
| US20080081370A1 (en) * | 2006-09-28 | 2008-04-03 | Peiman Hematti | Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells |
| DK2209888T3 (da) | 2007-10-12 | 2020-01-20 | Astellas Inst For Regenerative Medicine | Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler |
| US8501474B2 (en) * | 2007-10-15 | 2013-08-06 | Technion Research & Development Foundation Limited | Methods of generating embryoid bodies and uses of same |
| EP2620493B1 (en) | 2008-05-28 | 2019-03-27 | Ramot at Tel Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
| WO2010021993A1 (en) * | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
| WO2010114136A1 (ja) * | 2009-03-30 | 2010-10-07 | 第一三共株式会社 | 多能性幹細胞及び心筋細胞以外の分化細胞に対する細胞死誘導方法 |
| AU2010242780B2 (en) * | 2009-05-01 | 2016-04-21 | Puregraft Llc | Systems, methods and compositions for optimizing tissue and cell enriched grafts |
| CN102803472B (zh) * | 2009-06-25 | 2014-04-23 | 吉隆公司 | 去除了外来表型的由多能干细胞分化的子代细胞 |
| US9018010B2 (en) | 2009-11-12 | 2015-04-28 | Technion Research & Development Foundation Limited | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| IL281453B (en) | 2009-11-17 | 2022-07-01 | Astellas Inst For Regenerative Medicine | Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells |
| US9029145B2 (en) | 2010-04-08 | 2015-05-12 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
| WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| JP6037393B2 (ja) * | 2011-03-29 | 2016-12-07 | 国立大学法人 鹿児島大学 | 幹細胞における腫瘍化原因細胞の除去方法 |
| US10745468B2 (en) | 2011-12-22 | 2020-08-18 | Kota Biotherapeutics, Llc | Compositions and methods for modified B cells expressing reassigned biological agents |
| US10233424B2 (en) | 2011-12-22 | 2019-03-19 | Elwha Llc | Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin |
| US9175072B2 (en) | 2011-12-22 | 2015-11-03 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen |
| US8962315B2 (en) | 2011-12-22 | 2015-02-24 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen |
| WO2013134015A2 (en) | 2012-03-05 | 2013-09-12 | Wake Forest University Health Sciences | Non-viral episomal suicide construct |
| CN120796168A (zh) | 2013-06-11 | 2025-10-17 | 哈佛学院校长同事会 | SC-β细胞以及用于产生其的组合物和方法 |
| WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
| WO2016100898A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof |
| CN107614678B (zh) | 2014-12-18 | 2021-04-30 | 哈佛学院校长同事会 | 干细胞来源的β细胞的产生方法及其使用方法 |
| EP3234110B1 (en) | 2014-12-18 | 2024-02-28 | President and Fellows of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| CN109563482A (zh) | 2016-06-10 | 2019-04-02 | 埃尔瓦有限公司 | 含表达异于分泌免疫球蛋白和细胞溶解功能的膜免疫球蛋白的b淋巴细胞系的组合物和方法 |
| KR102106895B1 (ko) * | 2017-02-16 | 2020-05-07 | 고려대학교 산학협력단 | 골재생 효능이 우수한 골질환 예방 또는 치료용 조성물 |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| JP2020535834A (ja) | 2017-10-03 | 2020-12-10 | エスディーエフ バイオファーマ インコーポレイテッド | 遺伝子修飾されたベータ細胞による糖尿病の治療 |
| EP3710021A4 (en) | 2017-11-15 | 2021-08-11 | Semma Therapeutics, Inc. | ISLAND CELL MANUFACTURING COMPOSITIONS AND METHOD OF USE |
| WO2020033879A1 (en) | 2018-08-10 | 2020-02-13 | Semma Therapeutics, Inc. | Stem cell derived islet differentiation |
| EP4314244B1 (en) | 2021-03-23 | 2025-07-23 | Terumo BCT, Inc. | Cell capture and expansion |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| CN119184024A (zh) * | 2024-08-27 | 2024-12-27 | 南京农业大学 | 一种提高动物早期胚胎定植数量和促进胚胎发育的方法 |
| CN119709646A (zh) * | 2024-09-14 | 2025-03-28 | 青岛阿尔泰基因工程有限公司 | 一种治疗颅咽管瘤的慢病毒及其制备方法和应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959313A (en) | 1987-06-22 | 1990-09-25 | The Jackson Laboratory | Cellular enhancer for expressing genes in undifferentiated stem cells |
| US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| US5068191A (en) * | 1989-08-31 | 1991-11-26 | The Biomembrane Institute | Purified histo-blood group a glycosyltransferase and antibodies thereto |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
| US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
| NZ256154A (en) | 1992-07-27 | 1997-02-24 | California Inst Of Techn | Production of mammalian multipotent neural stem cells, antibodies |
| US5672499A (en) | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
| US5766948A (en) | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
| GB9308271D0 (en) * | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5409813A (en) * | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US6015671A (en) * | 1995-06-07 | 2000-01-18 | Indiana University Foundation | Myocardial grafts and cellular compositions |
| US6204431B1 (en) * | 1994-03-09 | 2001-03-20 | Abbott Laboratories | Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk |
| US5489304A (en) | 1994-04-19 | 1996-02-06 | Brigham & Women's Hospital | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
| US5639618A (en) | 1994-05-13 | 1997-06-17 | Plurion, Inc. | Method of isolating a lineage specific stem cell in vitro |
| GB9417831D0 (en) | 1994-09-05 | 1994-10-26 | Biotech & Biolog Scien Res | Biological manipulation |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| GB9505663D0 (en) | 1995-03-21 | 1995-05-10 | Stringer Bradley M J | Genetically modified neural cells |
| US6117985A (en) * | 1995-06-16 | 2000-09-12 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched cell preparations |
| GB9526509D0 (en) | 1995-12-23 | 1996-02-28 | Univ Dundee | Gene control |
| GB9807935D0 (en) | 1998-04-14 | 1998-06-10 | Univ Edinburgh | Lineage specific cells and progenitor cells |
| WO1997032025A1 (en) | 1996-03-01 | 1997-09-04 | Regents Of The University Of Minnesota | Method for selective engraftment of drug-resistant hematopoietic stem cells |
| AU741438B2 (en) | 1996-08-26 | 2001-11-29 | Hemasure, Inc. | Method for removing tumor cells from tumor cell-contaminated stem cell products |
| IL129222A0 (en) | 1996-10-01 | 2000-02-17 | Geron Corp | Telomerase reverse transcriptase |
| GB9621383D0 (en) | 1996-10-14 | 1996-12-04 | Roslin Inst Edinburgh | Transgene expression |
| CA2279542A1 (en) | 1997-02-05 | 1998-08-06 | The General Hospital Corporation | Tolerance to natural antibody antigens |
| WO1998039427A2 (en) | 1997-03-06 | 1998-09-11 | University Of Massachusetts | Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| DE19727962A1 (de) | 1997-07-02 | 1999-01-14 | Juergen Hescheler | Fluoreszierende Proteine als zelltypspezifische Reporter |
| WO1999010535A1 (en) | 1997-08-22 | 1999-03-04 | Yale University | A process to study changes in gene expression in stem cells |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6482937B1 (en) | 1997-10-09 | 2002-11-19 | Biotransplant, Inc. | Porcine Oct-4 promoter |
| CA2307807C (en) | 1997-10-23 | 2008-09-02 | Andrea G. Bodnar | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
| WO1999027076A1 (en) | 1997-11-25 | 1999-06-03 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
| DE19757984A1 (de) | 1997-12-24 | 1999-07-01 | Bayer Ag | Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung |
| WO2000018885A1 (en) | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
| BR9908499A (pt) | 1998-03-02 | 2001-12-26 | Univ Massachusetts Public Inst | Linhagens celulares embrionárias ousemelhantes a tronco produzidas portransplante nuclear de espécies cruzado |
| GB9811859D0 (en) | 1998-06-02 | 1998-07-29 | Biotech & Biolog Scien Res | Biological manipulation |
| GB9819912D0 (en) | 1998-09-11 | 1998-11-04 | Univ Edinburgh | Propagation and/or derivation of embryonic stem cells |
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6087168A (en) | 1999-01-20 | 2000-07-11 | Cedars Sinai Medical Center | Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells |
| EP1147181B1 (en) | 1999-02-04 | 2004-05-12 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
| WO2001011011A2 (en) | 1999-08-05 | 2001-02-15 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
| US6458589B1 (en) * | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
| WO2001088104A2 (en) | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
| WO2002061033A2 (en) | 2000-11-27 | 2002-08-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Transfection of human embryonic stem cells |
| US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| US6921665B2 (en) * | 2000-11-27 | 2005-07-26 | Roslin Institute (Edinburgh) | Selective antibody targeting of undifferentiated stem cells |
-
2001
- 2001-02-13 US US09/783,203 patent/US6576464B2/en not_active Expired - Lifetime
- 2001-11-26 WO PCT/US2001/044309 patent/WO2002042445A2/en not_active Ceased
- 2001-11-26 ES ES01986488.3T patent/ES2544942T3/es not_active Expired - Lifetime
- 2001-11-26 CN CN2009102249802A patent/CN101928692A/zh active Pending
- 2001-11-26 KR KR10-2003-7007100A patent/KR20030081334A/ko not_active Withdrawn
- 2001-11-26 AU AU3768102A patent/AU3768102A/xx active Pending
- 2001-11-26 GB GB0313389A patent/GB2386120B/en not_active Expired - Fee Related
- 2001-11-26 JP JP2002545150A patent/JP2004523217A/ja active Pending
- 2001-11-26 CA CA 2434760 patent/CA2434760C/en not_active Expired - Fee Related
- 2001-11-26 IL IL15569501A patent/IL155695A0/xx active IP Right Grant
- 2001-11-26 AU AU2002237681A patent/AU2002237681B2/en not_active Ceased
- 2001-11-26 CN CNA018196470A patent/CN1478145A/zh active Pending
- 2001-11-26 EP EP01986488.3A patent/EP1337632B1/en not_active Expired - Lifetime
-
2002
- 2002-05-07 US US10/141,220 patent/US20030040111A1/en not_active Abandoned
-
2003
- 2003-04-30 IL IL155695A patent/IL155695A/en not_active IP Right Cessation
-
2006
- 2006-02-21 US US11/359,341 patent/US8426198B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/837,522 patent/US9023645B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20130273651A1 (en) | 2013-10-17 |
| WO2002042445A3 (en) | 2003-01-16 |
| CA2434760C (en) | 2013-09-24 |
| IL155695A0 (en) | 2003-11-23 |
| GB0313389D0 (en) | 2003-07-16 |
| EP1337632A2 (en) | 2003-08-27 |
| US6576464B2 (en) | 2003-06-10 |
| US20060134782A1 (en) | 2006-06-22 |
| CA2434760A1 (en) | 2002-05-30 |
| AU2002237681B2 (en) | 2007-03-22 |
| AU3768102A (en) | 2002-06-03 |
| CN101928692A (zh) | 2010-12-29 |
| EP1337632B1 (en) | 2015-05-20 |
| GB2386120B (en) | 2005-03-09 |
| WO2002042445A2 (en) | 2002-05-30 |
| KR20030081334A (ko) | 2003-10-17 |
| US9023645B2 (en) | 2015-05-05 |
| JP2004523217A (ja) | 2004-08-05 |
| US20020098582A1 (en) | 2002-07-25 |
| US8426198B2 (en) | 2013-04-23 |
| IL155695A (en) | 2007-10-31 |
| GB2386120A (en) | 2003-09-10 |
| US20030040111A1 (en) | 2003-02-27 |
| CN1478145A (zh) | 2004-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2544942T3 (es) | Células diferenciadas adecuadas para tratamiento humano | |
| Conti et al. | Neural stem cell systems: physiological players or in vitro entities? | |
| US12116594B2 (en) | Methods for differentiating cells | |
| DK2694644T3 (en) | Priming of pluripotent stem cells for neural differentiation | |
| Tada et al. | Pluripotency of reprogrammed somatic genomes in embryonic stem hybrid cells | |
| Su et al. | Direct conversion of fibroblasts into neural progenitor-like cells by forced growth into 3D spheres on low attachment surfaces | |
| EP3000877A1 (en) | Neural stem cells | |
| JP2008099662A (ja) | 幹細胞の培養方法 | |
| CN108350431A (zh) | 用于确定候选药物的功效特征的方法 | |
| JP2017525351A (ja) | 多能性幹細胞の培養用培地 | |
| CN114174493A (zh) | 使用带电表面从诱导多能干细胞产生多个谱系的方法 | |
| CN110396499A (zh) | 一种诱导神经干细胞的方法及其应用 | |
| EP2721143A1 (en) | Growth of cells | |
| CN101563449A (zh) | 干细胞培养基及干细胞培养方法 | |
| CN101402943B (zh) | 一种体外诱导和培养多潜能干细胞的方法 | |
| CN113272422B (zh) | 用于无载体3d球体悬浮培养中视网膜神经元生成的方法和组合物 | |
| Zhang | Embryonic stem cells for neural replacement therapy: prospects and challenges | |
| Parsons | Human stem cell derivatives retain more open epigenomic landscape when derived from pluripotent cells than from tissues | |
| Jang et al. | Neural stem cells derived from epiblast stem cells display distinctive properties | |
| ES2351620T3 (es) | Procedimiento de preparación de células aviarias diferenciadas y genes implicados en el mantenimiento de la pluripotencia. | |
| Perugini et al. | Hyperbranched poly (ϵ-lysine) substrate presenting the laminin sequence YIGSR induces the formation of spheroids in adult bone marrow stem cells | |
| WO2023077050A1 (en) | Dopaminergic neurons comprising mutations and methods of use thereof | |
| CN102816796B (zh) | c-Jun的N端缺失诱导多能性干细胞的方法和应用 | |
| Zheng et al. | Comparation of enhanced green fluorescent protein gene transfected and wild-type porcine neural stem cells | |
| Kramer et al. | Chondrocytes derived from mouse embryonic stem cells |